Chiasma, Inc. (CHMA) News
Filter CHMA News Items
CHMA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CHMA News Highlights
- CHMA's 30 day story count now stands at 7.
- Over the past 20 days, the trend for CHMA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- LAW, BOCH and PULM are the most mentioned tickers in articles about CHMA.
Latest CHMA News From Around the Web
Below are the latest news stories about Chiasma Inc that investors may wish to consider to help them evaluate CHMA as an investment opportunity.
When Will Chiasma, Inc. (NASDAQ:CHMA) Breakeven?Chiasma, Inc. ( NASDAQ:CHMA ) is possibly approaching a major achievement in its business, so we would like to shine... |
Pulmatrix appoints Director Anand VaradanPulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. |
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates RAVN, BOCH, ONEM, CHMA; Shareholders are Encouraged to Contact the FirmNEW YORK, July 24, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Raven Industries, Inc. (NASDAQ: RAVN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to CNH Industrial N.V. for $58.00 per share. If you are a Raven shareholder, click here to learn more about your rights and options. Bank of Commerce Holdings (NASDAQ: BOCH) concerning poten |
SHAREHOLDER ALERT: WeissLaw LLP Reminds ONEM, BOCH, CHMA, and QTS Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates WRI, WBT, CHMA, XOG, USCR, ONEM; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
SHAREHOLDER ALERT: WeissLaw LLP Reminds ONEM, BOCH, CHMA, and MDCA Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
SHAREHOLDER ALERT: WeissLaw LLP Reminds BOCH, PLBN, CORE, and CHMA Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HGV, CHMA, ONDS, BOCH; Shareholders are Encouraged to Contact the FirmNEW YORK, July 03, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Hilton Grand Vacations Inc. (NYSE: HGV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Diamond Resorts International, Inc. If you are a Hilton Grand shareholder, click here to learn more about your rights and options. Chiasma, Inc. (NASDAQ: CHMA) concerning potential |
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines AgencySubmission supported by previously announced data from Phase 3 MPOWERED™ studyNEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it has submitted a Marketing Authorization Applic |